Different transcriptional subgroups of GBM enrich for distinct combinations of cancer drivers, including frequent mutations in TP53, PTEN, CDKN2A, NF1, EGFR, IDH1, and TERT promoter, as well as EGFR, PDGFRA, CDK4 amplification (Brennan et al. 2013). This evidence concerns the gene CDKN2A and glioblastoma.